Comparative models targeting Gba1 deletion prenatally versus postnatally, combined with transcriptomic profiling, will be essential for defining the evolving role of microglia across disease stages and for developing more effective therapeutic platforms for nGD and related lysosomal disorders (Table 2). The gene discussed is GBA1; the disease is lysosomal storage disease.